Boris Weiss, Chief Executive Officer of Medipure Pharmaceuticals recently talked to us about the numerous clinical trials his company has in development throughout the world, including studies in Canada, United States, India, and Croatia.

Medipure’s focus is on developing proprietary cannabinoid-derived medications to treat a number of conditions, including pain, mood disorders, dermatitis, psoriasis, NASH (non-alcoholic steatohepatitis), and various cancers.

For more information, visit